HE1 ECONOMIC EVALUATION OF A 90-DAY RETAIL PRESCRIPTION DRUG PROGRAM IN A PHARMACY BENEFIT MANAGEMENT SETTING  by Sun, SX et al.
A12 Abstracts
degree to which health problems interfere with ability to perform
job roles. The WPQ includes physical, mental (concentration),
time (interruptions and adherence to schedule) and output
(ability to handle workload) scales and a WPQ Index is com-
puted to estimate overall productivity loss. In MATRIX, WPQ
scores were compared to the King’s Health Questionnaire
(KHQ), a validated OAB-speciﬁc quality of life (QOL) instru-
ment. We examined the relationship between WPQ scores and
conceptually-related KHQ domains at baseline, and the sensi-
tivity of the WPQ to change in related KHQ measures at 3
months. RESULTS: A total of 1112 employed OAB patients were
enrolled in MATRIX, from 327 US sites. The number of
responses available for each scale at baseline were: time (n = 830,
75%); physical (n = 866, 78%); mental (n = 818, 74%); output
(n = 814, 73%). A WPQ Index was computable for 740 partic-
ipants. Spearman correlations between the KHQ physical limi-
tations domain and the WPQ physical scale was 0.297, and
between the KHQ role limitations and WPQ index score was
0.356. The WPQ appears to be sensitive to change over time,
with WPQ physical scale scores and KHQ physical limitations
score both decreasing at three months and the WPQ Index and
KHQ role limitations also both decreasing at three months.
CONCLUSION: Results suggest that the WPQ is a valid
measure of work productivity in patients with OAB.
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OBJECTIVES: To assess risk indicators for self-reported joint
pain and motion limitation outcomes in hemophilia patients.
METHODS: The Hemophilia Utilization Group Study (HUGS)
examines prospectively the cost and burden of hemophilia,
including arthropathy, quality of life, and economic impact in
patients aged 2 to 65. Parents/patients completed a standardized
interview, including factor use patterns and assessment of joint
pain and motion limitation. Clinical chart reviews were per-
formed to identify the presence of inhibitor antibodies and hemo-
philia severity. Logistic regression was used to evaluate the
association between the factors from the Health Behavioral
Model (predisposing, enabling, need, and health behavior) and
the likelihood of joint pain or motion limitation. RESULTS: Of
the 128 patients with complete outcome data, 70(55%) were
adults, 32(25%) reported joint pain most or all the time,
49(39%) reported severe motion limitation in at least one joint.
Mean age was 23.8 (16.2) years. Risk indicators associated with
joint pain were: 1) predisposing: increasing age (OR = 1.1; 95%
CI = 1.03, 1.1); parent/patient not married/without partner (OR
= 5.7; 1.8, 18.3), and 2) enabling: increasing number of prob-
lems getting care at the hemophilia treatment center (OR = 1.9;
1.03, 3.6). No association was found in need (ever had inhibitor)
and health behaviors (use of factor). Risk indicators associated
with severe motion limitation were: 1) predisposing: increasing
age (OR = 1.1; 95% CI = 1.07, 1.2); parent/patient not
married/without partner (OR = 3.9; 1.3, 12.2); severe hemo-
philia (OR = 21.0; 2.8, 158.9). CONCLUSION: Increasing age,
lack of a support system and more severe hemophilia are useful
characteristics for clinicians to identify patients at greater risk
for joint pain and limitation. Early identiﬁcation of these factors,
which are a major source of disability, may be helpful in avoid-
ing decreased health status and increased medical costs. Address-
ing barriers to receipt of care is of particular import for those
most at risk.
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OBJECTIVES: Abnormal uterine bleeding (AUB) affects up to
30% of women of reproductive age. The purpose of this study
is to quantitatively estimate the impact of AUB on health-related
quality of life (HRQoL). METHODS: A systematic literature
review of studies reporting the impact of AUB or its treatment
on HRQoL published from 1980 to 2005 was conducted from
the PubMed database. We conducted a meta-analysis of eight
studies providing HRQoL scores derived from the 36-item Short
Form Health Survey Questionnaire (SF-36); only baseline SF-36
scores prior to treatment were analyzed. Both random-effect and
ﬁxed-effect models were created and used. The scores were com-
pared with US national norms (weighted average across age
groups 18–24, 25–34, 35–44, and 45–54, obtained from the SF-
36 Health Survey Manual & Interpretation Guide). A subgroup
analysis was conducted to examine whether or not the SF-36
scores differ according to the mean age of each subgroup.
RESULTS: Women with AUB had lower SF-36 scores (worse
health) in all eight subscales; the most signiﬁcantly affected were
Physical Role Functioning and Emotional Role Functioning sub-
scales, which relate to work productivity and other daily activi-
ties. The scores in these two dimensions were approximately 20
points lower than the US population norms (60.3 vs. 84.0 and
62.3 vs. 81.1; highest score = 100). In 6 of the 8 subscales, the
scores for AUB were below the 25th percentile of those for US
national norms (Physical Functioning, Physical Role Function-
ing, Pain, Vitality, Social Functioning, and Emotional Role Func-
tioning). The subgroup analysis suggested that older women had
lower SF-36 scores than younger women; however, the small
number of studies precludes the forming of a deﬁnitive conclu-
sion. CONCLUSIONS: AUB has a signiﬁcant impact on
women’s HRQoL. Treatment for AUB should consider improv-
ing HRQoL status.
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OBJECTIVES: To evaluate the impact of a 90-day retail program
on prescription drug expenditures in a pharmacy beneﬁt man-
agement organization. METHODS: This study was based on
prescription records from pharmacy claims database for a time
period from January 1, 2003 to August 31, 2005. A retrospec-
tive cohort study design with one-year pre period and one-year
post period was employed. Propensity scores were used to match
the study and control clients in terms of patient and client char-
acteristics. Per prescription cost, per member per month (PMPM)
total, plan and member costs and generic utilization rate were
the targeted outcomes. RESULTS: The study group included 25
clients (106,718 lives) enrolled in 90-day retail program, and the
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control group included 25 propensity score matched clients
(95,054 lives) not enrolled in the program. In the study group,
the average total cost per prescription (normalized to 90-day
supply) was signiﬁcantly lower in 90-day retail than in mail
service and 30-day retail ($165.9 vs. $170.65 vs. $185.9). The
generic utilization rate in 90-day retail was higher than in mail
service but lower than 30-day retail (38.36% vs. 37.38% vs.
39.75%). From the pre to post period, in study group, PMPM
total, plan and member costs among eligible lives increased by
7% (from $29.54 to $31.60), 6.5% (from $22.29 to $23.73) and
7.3% (from $7.11 to $7.63). In the control group, PMPM total,
plan and member increased by 10.1% (from $30.16 to $33.22),
10.4% (from $22.33 to $24.65) and 9.3% (from $7.72 to
$8.43). It was estimated that this 90-day retail program had
PMPM cost savings of $0.89, $0.79 and $0.10 for the total, plan
and members. CONCLUSIONS: A 90-day retail program was
found to have decreased total, health plan and member pre-
scription drug costs.
HE2
ESTIMATING OUT-OF-POCKET PHARMACEUTICAL
EXPENDITURES UNDER THE NEW MEDICARE DRUG LAW
FOR PATIENTS WITH MENTAL DISORDERS—AN ANALYSIS OF
CLAIMS DATA FROM RETIREE MEDICAL PLANS
Gibson TB1, Ozminkowski RJ1, Mark T2, Costa L3
1Thomson Medstat, Ann Arbor, MI, USA, 2Thomson Medstat,
Washington, DC, USA, 3Research Data Solutions, Boston, MA, USA
OBJECTIVES: Estimate out-of-pocket pharmacy expenditures
for elderly retirees with employer-sponsored coverage, under the
standard Medicare drug plans that began on January 1, 2006.
METHODS: Data came from the Medstat MarketScan Medicare
Database, for 2004. Data included all medical and pharmacy
claims for 1,220,902 seniors enrolled in retiree plans offered by
large employers. (About 30% of non-institutionalized Medicare
enrollees have retiree coverage.) Payments covered by the
Medicare program and by private insurance were included.
Analyses focused on 30,681 patients with diagnoses of depres-
sion, anxiety disorder, or schizophrenia in 2004. We estimated
the out-of-pocket payments that would have been incurred by
these beneﬁciaries, if the Medicare drug law had been in effect
during 2004. We also estimated how long it may take to enter
the “donut hole” where coverage stops (i.e., that period during
which total pharmacy expenditures range from $2251 to $5100).
RESULTS: Mean total pharmacy payments for these mental
health patients were higher than payments for other patients
with retiree coverage ($4491 for depression patients, $3364 for
anxiety patients, and $5321 for schizophrenia patients, versus
$2587 for the average Medicare beneﬁciary). The average mental
health patient ﬁlled over 50 prescriptions for all medical prob-
lems. More than 30% would have entered the donut hole. Schiz-
ophrenia patients would have entered after about 4 months (in
April). Depression patients would fall into the donut hole after
about 6 months, while anxiety patients would enter after about
9 months, on average. Average out-of-pocket pharmacy pay-
ments under the new law would have ranged from $1858 for
anxiety patients to $2407 for schizophrenia patients. CON-
CLUSIONS: Most patients with these psychiatric conditions will
face high out of pocket costs, and will be faced with a donut
hole of no coverage. Implications for adherence to pharma-
cotherapy and overall health should be considered by doctors
and policy makers.
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OBJECTIVES: The research objective is to examine whether
there are racial and ethnic disparities in health expenditures and
health status. Health expenditure and health status are examined
together because theoretically higher spending on health care ser-
vices should lead to better health status. METHODS: The data
were drawn from a nationally representative sample of non-
institutionalized U.S. civilians in the Medical Expenditure Panel
Survey (1996 and 2001). The racial and ethnic disparities were
examined separately by comparing non-Hispanic whites, non-
Hispanic blacks, and Hispanic whites (Hispanic blacks were
excluded due to small sample size). Disparities in self-perceived
health status (poor, fair, good, very good, and excellent) were
compared across racial and ethnic groups using an ordered logis-
tic regression. Disparities in health expenditure were compared
using linear regression (A two-part model was also used to
conﬁrm the ﬁndings). RESULTS: The study sample included
31,258 non-Hispanic whites, 7349 non-Hispanic black, and
11,248 Hispanic whites. There was an overall signiﬁcantly better
self-perceived health status among non-Hispanic whites than
non-Hispanic blacks and Hispanic whites: non-Hispanic blacks
were 79.29% as likely to report a better self-perceived health
status category compared to non-Hispanic whites (P < 0.01);
Hispanic whites were 77.06% as likely to report a better self-
perceived health status category compared to non-Hispanic
whites (P < 0.01). Overall, non-Hispanic blacks and Hispanic
whites spent $690 less (P < 0.01) and $1365 (P < 0.01) less than
non-Hispanic whites every year. The racial disparities in health
expenditures and self-perceived health status were signiﬁcant
after adjusting for confounders; ethnic disparities in health
expenditures were still signiﬁcant but ethnic disparities in health
status were not signiﬁcant. CONCLUSIONS: Compared with
non-Hispanic whites, non-Hispanic blacks have lower health
expenditure and worse self-perceived health status; Hispanic
whites have lower expenditures but similar self-perceived health
status. Further analysis is warranted to examine the causes for
different patterns of racial and ethnic disparities.
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Evidence from US national health surveys suggests that age-
adjusted prevalence of stroke risk factors varies considerably by
race/ethnicity. What is not known is whether resource use among
hospitalized stroke patients, and the associated cost of inpatient
care, differ by race/ethnicity. OBJECTIVE: To assess racial/ethnic
differences in hospital length of stay and cost related to inpatient
treatment of intracerebral hemorrhage (ICH) in US hospitals.
METHODS: The 2002 Health care Cost and Utilization Project
database was used to examine short-stay acute-care hospital dis-
charges among adult ICH patients. This dataset includes all dis-
charges from 995 hospitals in 35 states. Patients were identiﬁed
